Otsuka's Voyxact preserved kidney function over 12 months in IgA nephropathy patients, new eGFR data show, as the company pursues full FDA approval.
June 4, 2026 06:31 PM EDT
R&DPharma
Otsuka touts new IgAN evidence as it seeks full approval for Voyxact
Nicole DeFeudis
Otsuka Pharmaceutical reported new evidence on Thursday that it thinks will help support a full approval for its monoclonal antibody Voyxact in a chronic autoimmune …
Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
Outlook Therapeutics resubmits biologics license application for ONS-5010
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
Novel Biologic Performs Well in IgG4-Related Disease
VIDEO: Expert shares personal experience with IgA nephropathy treatment landscape
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the…
The FDA granted accelerated approval for sibeprenlimab-szsi to reduce proteinuria for adults with primary immunoglobulin A…
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
The FDA has proposed to withdraw its approval of avacopan for ANCA-associated vasculitis, alleging that employees of the original…
After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. | After a…
After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again…
